CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals (Nasdaq: IDRA) today announced that the first patient has been dosed in a Phase 1b trial evaluating IMO-2055 in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC). IMO-2055 is a novel agonist of Toll-like Receptor (TLR) 9. Tarceva and Avastin are targeted agents approved by the U.S. Food and Drug Administration for the treatment of NSCLC.
